Wedbush Begins Coverage on Aquestive Therapeutics (AQST)

Analysts at Wedbush initiated coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report issued on Wednesday, Marketbeat reports. The firm set an “outperform” rating and a $33.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 72.87% from the company’s previous close.

Several other research analysts have also issued reports on the company. Royal Bank of Canada began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating and a $23.00 target price for the company. JMP Securities began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating and a $29.00 target price for the company. Finally, BMO Capital Markets began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating for the company.

Shares of NASDAQ:AQST traded up $0.62 during trading hours on Wednesday, hitting $19.09. 2,170 shares of the company’s stock traded hands, compared to its average volume of 121,162. Aquestive Therapeutics has a 1 year low of $14.75 and a 1 year high of $19.30.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, September 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($1.66). The business had revenue of $13.93 million during the quarter.

In other Aquestive Therapeutics news, Director Douglas K. Bratton bought 165,000 shares of the company’s stock in a transaction on Tuesday, July 24th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $2,475,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Story: Market Capitalization and Individual Investors

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply